<DOC>
	<DOCNO>NCT01741155</DOCNO>
	<brief_summary>The purpose study estimate compare objective response rate SPI-1620 administer combination docetaxel patient NSCLC determine safety SPI-1620 administer combination docetaxel .</brief_summary>
	<brief_title>Study SPI-1620 Combination With Docetaxel Versus Docetaxel Alone Patients With Non Small-cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This two part study . In Single Arm Part , patient receive 11 μg/m2 SPI-1620 IV follow docetaxel 75 mg/m2 IV . Cycles continue every 3 week progression intolerable toxicity . Overall 27 patient enrol Single Arm Part . If 6 response ( CR/PR ) observe group Randomized Part initiate . In Randomized Part approximately 200 patient ( 100 per arm ) randomize receive SPI-1620 plus docetaxel docetaxel alone . In experimental arm , patient receive 11 μg/m2 SPI-1620 IV follow docetaxel 75 mg/m2 IV administer 3-week cycle progression intolerable toxicity . In control arm , patient receive 75 mg/m2 docetaxel 3-week cycle progression intolerable toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced metastatic NSCLC fail one prior platinumcontaining chemotherapy Measurable disease per RECIST v. 1.1 ECOG performance status 0 , 1 2 Adequate bone marrow , liver renal function More one prior chemotherapy regimen metastatic NSCLC Known , uncontrolled CNS metastasis Significant circulatory disorder past 6 mo . Concomitant treatment phosphodiesterase inhibitor Uncontrolled orthostatic hypotension , asthma COPD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>